The product designated as Terbinafine Ointment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is unformulated terbinafine hydrochloride, CAS 78628-80-6, an allylamine antifungal supplied as a white to almost white crystalline powder for downstream veterinary dosage-form manufacture. The material is not a finished ointment, tablet, medicated premix, or injectable solution; it is an active pharmaceutical ingredient that must be formulated, validated, and registered according to regional veterinary requirements. The designation “veterinary grade” is not a harmonized pharmacopoeial moniker; it indicates that the material is released for veterinary pharmaceutical use with route-specific microbial, endotoxin, residual solvent, and particle size controls. Its primary mechanism of action is inhibition of squalene epoxidase in fungal ergosterol biosynthesis, leading to accumulated squalene and fungal membrane dysfunction. This target differs from the lanosterol 14α-demethylase step used by azole antifungals, which has direct consequences for susceptibility testing and resistance interpretation.

Because the product is an unformulated API, it should not be interchanged with a ready-to-use medicated premix or a compounded ointment concentrate. No carrier, preservative, antioxidant, or overage is included; therefore, a formulator must add the appropriate overage based on stability data and must validate that the active substance can be homogeneously incorporated into the selected matrix. If the API is transferred from one supplier to another, even a certificate-of-analysis match on assay may be insufficient; particle morphology, residual solvent class, and trace metal profile can differ enough to shift dissolution, segregation, or emulsion stability. Supplier qualification for this material normally includes comparative HPLC impurity and dissolution profiles on a pilot formulation, not just a paper audit.

Salt form, crystallinity, and analytical release controls

The hydrochloride salt, formula C21H25N·HCl with molecular weight 327.89 g/mol, is preferred for formulation because its crystalline form can be milled reproducibly and its organic-solvent wetting supports lipophilic ointment and non-aqueous solution processing. Aqueous solubility is limited and pH-dependent; the protonated salt dominates at acidic pH, while neutral-to-alkaline conditions can reduce solubility and precipitate free base. Release testing typically includes IR identification, HPLC assay against a reference standard, related substances by reverse-phase HPLC, water by Karl Fischer titration, and residual solvents by headspace GC. Water and residual solvent limits are derived from the current Ph. Eur. monograph for terbinafine hydrochloride, from VICH GL11 impurity reporting principles, and from VICH GL18 solvent classification. X-ray powder diffraction is used when the synthesis or milling route changes; a supplier should provide the reference diffractogram for any micronized or air-jet milled grade because crystal habit, specific surface area, and amorphous content influence dissolution, electrostatic charge, and content uniformity. If an alternate salt or base is requested for a non-sterile formulation, the release file must state the exact form because the free base and hydrochloride salt are not interchangeable on a weight-for-weight basis.

In a tablet or capsule development line, direct compression of unmilled terbinafine HCl is usually abandoned because acicular crystal habit and static charge create die-fill variation. Low-shear blending in a V-blender or bin blender can induce segregation when the API has a lower bulk density than direct-compression diluents. Production-scale batches therefore move to high-shear wet granulation or roller compaction. For wet granulation, high-shear granulator impeller speeds of 100–250 rpm and chopper speeds of 1000–1500 rpm are typical for a 600 L bowl, but scale-up requires matching Froude number and corrected swept volume rather than simply holding rpm constant. Roller-compacted granules are screened through a 1.0 mm screen and blended with magnesium stearate at not more than 1.0% w/w, added as the final blend step to minimize dissolution delay. Blend uniformity is monitored using stratified sampling and a relative standard deviation target of not more than 5.0% during process validation; finished dosage units are tested according to USP <905>. Dissolution testing under USP <711> must use a medium that maintains sink conditions; the exact medium is selected from solubility screening because terbinafine HCl is not freely water-soluble.

How is the particle size boundary set differently for ointment, injection, and premix processing paths?

For this API, particle size control is the most route-sensitive material attribute. In an ointment, the dispersed solid must be below the tactile threshold and remain suspended in a lipophilic base without forming a gritty layer. Micronization is therefore used to bring the mass-median diameter to roughly 20–30 µm; oversized particles above 75 µm are considered a high-risk fraction for grittiness and sedimentation during storage. The milled API is levigated with a portion of the ointment vehicle before it is added to the full batch, and final homogenization may use a three-roll mill or vacuum homogenizer to remove agglomerates. For injectable processing, the API is expected to dissolve completely and pass through a 0.22 µm filter; particle size distribution at release is less critical than dissolution behaviour and filtration compatibility in a co-solvent or buffered system. For dry premixes and feed granules, particle size must be balanced against segregation potential. A micronized material with D90 ≤ 20 µm can adhere electrostatically to mixer surfaces and may produce feed distribution failure, while a coarse material can segregate from fine carriers. Stepwise geometric dilution in a ribbon mixer or double-cone blender is used until the active concentration reaches the labelled premix specification.

Among the dosage-form paths, injectable formulation development has the narrowest processing window. The hydrochloride salt is usually dissolved in a pre-chilled co-solvent/water blend to minimize localized hydrolysis, and pH is adjusted in small increments because overshooting the upper pH boundary can precipitate free base; re-acidification may not fully redissolve the precipitate without heating. Holding time between complete dissolution and 0.22 µm filtration is therefore validated, and pre-filtration bioburden is monitored against the sterilizing-filter challenge level. For terminal heat sterilization, forced-degradation data must show acceptable impurity formation; otherwise aseptic fill is required. The selection of container-closure materials is not neutral: elastomeric closures may sorb the API or leach oligomers, and compatibility studies at 25 °C and 40 °C are used to detect pH drift, precipitation, or loss of assay. A nitrogen overlay may be required if oxygen-sensitive co-solvents or long-term storage are part of the primary packaging.

Air-jet milling of the hydrochloride salt should be treated as a process validation risk rather than a simple size-reduction step. The mill is operated with filtered compressed air or nitrogen; classifier speed, feed pressure, and grinding pressure are set to keep the D90 inside the route-specific range while limiting coarse tails. Milling trials require before-and-after XRPD because mechanical energy can create crystal disorder or partial amorphous domains. The resulting high-specific-surface powder may pick up moisture if drums are opened outside a humidity-controlled suite. Production areas are usually maintained at 40–60% RH to reduce static charge and prevent particle clumping. Extended open-drum handling above 60% RH should be avoided because moisture uptake can increase particle agglomeration and reduce the efficiency of subsequent dry blending. The API should be kept away from strong oxidizing agents during milling and from prolonged contact with open steam or strong alkali in cleaning operations. If a batch shows high static adhesion, stainless-steel equipment bonding and controlled discharge rates are preferred over adding excessive glidant because glidant over-addition can reduce dissolution rate and tablet hardness.

In oral and topical solution processing, water alone is insufficient to hold the API in solution across the pH range acceptable for veterinary administration. Ethanol, propylene glycol, and buffered aqueous phases are combined after solubility screening at 5 °C, 25 °C, and 40 °C to ensure that transient temperature excursions during shipment do not cause precipitation. pH is controlled with USP <791> or Ph. Eur. 2.2.3 and is kept in a range that preserves the soluble salt while avoiding unacceptable injection-site irritation. If cyclodextrin complexation is required, the inclusion ratio is established by phase-solubility measurement at constant pH and ionic strength. Sterile filtration should be validated with the actual production filter and contact time; PVDF or PES membranes are generally selected because co-solvents can damage cellulose ester membranes. The solution is then filled aseptically unless forced-degradation data justify terminal heat sterilization. For feed premixes, the API is not added as a neat powder directly to final feed. A medicated premix is prepared by geometrically dispersing the API into a suitable carrier and mixing in a ribbon mixer until stratified sampling shows acceptable homogeneity across defined sampling points. Mixing time is not extended indefinitely; over-mixing can break agglomerates and reintroduce segregation or electrostatic particle separation.

When antifungal susceptibility testing forces a choice between allylamine and azole mechanisms

Considering the primary mechanism of action, terbinafine HCl differs from azole veterinary antifungals in both target enzyme and pharmacodynamic behavior. Terbinafine inhibits squalene epoxidase, producing squalene accumulation and membrane disruption; this is often fungicidal against dermatophytes. Azoles such as ketoconazole, miconazole, and itraconazole inhibit lanosterol 14α-demethylase, a downstream cytochrome P450-dependent step, and may be primarily fungistatic. The distinction is important for susceptibility testing. CLSI M38-A2 broth dilution testing is appropriate for filamentous fungi, but veterinary clinical breakpoints are not as widely standardized as human interpretive categories. In vitro susceptibility should be read against wild-type distribution data for the target animal and region, not automatically extrapolated from human medicine. Terbinafine HCl also differs from the topical allylamine naftifine in molecular weight, salt characteristics, and formulation options, although both compounds share the squalene epoxidase target. Cross-resistance with azoles is not inevitable because the target enzymes differ; however, efflux pump upregulation or mutations in the squalene epoxidase gene can reduce susceptibility. Published veterinary-specific resistance surveillance data for dermatophyte isolates remain less extensive than human onychomycosis data, so susceptibility testing is warranted when an outbreak or poor clinical response suggests reduced sensitivity.